首页|肿瘤患者血小板输注致迟发性血清学输血反应的临床特征及输血策略

肿瘤患者血小板输注致迟发性血清学输血反应的临床特征及输血策略

扫码查看
目的 分析肿瘤患者血小板输注后发生迟发性血清学输血反应(delayed serologic transfusion reactions,DSTR)的临床表现,并探讨其输血策略。方法 对本院 2015 年 1 月 1 日至 2023 年 6 月 30 日期间所有输注血小板后,抗体筛查阳性患者的相关临床资料及实验室检查结果进行分析,统计DSTR的发生率、临床特点及输血策略。结果 本研究共查阅 2 553 名患者 6 057 例次血小板输注。8 名患者发生了DSTR,共接受血小板 21 个治疗量,5 名患者后续输注红细胞。检测到Rh系统抗体 7 名(抗-E4 名,抗-c、E1 名,抗-C1 名和抗-c1 名)和Kell系统抗体 1名。结论 肿瘤患者输注血小板后也可能发生DSTR,产生红细胞抗体,再次输血时需密切关注抗体情况,进行匹配性输注。
Clinical characteristics and transfusion strategies of delayed serological transfusion reactions caused by platelet transfusion in tumor patients
Objective To analyze the clinical manifestations of delayed serological transfusion reactions(DSTR)after platelet transfusion in tumor patients,and to explore the transfusion strategy.Methods Clinical data and laboratory test re-sults of patients with positive antibody screening were analyzed after platelet transfusion in our hospital from January 1,2015 to June 30,2023,and the incidence rate,clinical characteristics and transfusion strategy of patients with DSTR were ana-lyzed.Results A total of 2 553 patients with 6 057 platelet transfusions were reviewed.Eight patients developed DSTR and received a total of 21 therapeutic amounts of platelets,and 5 patients were subsequently transfused with red blood cells.Rh system antibodies were detected in 7 cases(4 anti-E,1 anti-c/E,1 anti-C and 1 anti-c)and Kell system antibodies in 1 case.Conclusion Tumor patients may also develop DSTR after platelet transfusion.It is necessary to pay close attention to the antibody situation and perform matched transfusion when transfusing blood again.

tumor patientsplatelet transfusiondelayed serological transfusion reactions(DSTR)

刘敏、彭涛、于晶晶、赵瑞娟、房伟伟、蔡鹃、陈思梦、李喜莹

展开 >

国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院输血科,北京 100021

肿瘤患者 血小板输注 迟发性血清学输血反应

中国医科院肿瘤医院管理研究课题

LC2021D05

2024

中国输血杂志
中国输血协会 中国医学科学院输血研究所

中国输血杂志

CSTPCD
影响因子:1.279
ISSN:1004-549X
年,卷(期):2024.37(5)
  • 15